Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

A push for comparative effectiveness: US initiatives aim to empower patients, physicians. Interview by Bridget M. Kuehn.

Clancy CM.

JAMA. 2012 Apr 18;307(15):1570-1. doi: 10.1001/jama.2012.471. No abstract available.

PMID:
22511672
2.

Spending limited health care dollars on what works best: the promise of comparative effectiveness research.

Stein J.

N C Med J. 2010 May-Jun;71(3):265-6. No abstract available.

PMID:
20681501
3.
4.

Lessons from comparative effectiveness research methods development projects funded under the Recovery Act.

Zurovac J, Esposito D.

J Comp Eff Res. 2014 Nov;3(6):601-7. doi: 10.2217/cer.14.64.

PMID:
25494566
5.

The American Reinvestment and Recovery Act investment in comparative effectiveness research: lessons learned and implications for future investments.

Dormer L, Greenfield S.

J Comp Eff Res. 2014 Nov;3(6):559. doi: 10.2217/cer.14.75. No abstract available.

6.

How a unique provision in the American Recovery and Reinvestment Act set a foundation for the Patient-Centered Outcomes Research Institute.

Selby J, Slutsky J.

J Comp Eff Res. 2014 Nov;3(6):565-6. doi: 10.2217/cer.14.59. No abstract available.

PMID:
25494560
7.

Science and the stiumulus. Medicine under the microscope.

Marshall E.

Science. 2009 Nov 27;326(5957):1183-5. doi: 10.1126/science.326.5957.1183. No abstract available.

PMID:
19965447
9.

American Recovery and Reinvestment Act investments in data infrastructure.

O'Day B, Kieffer T, Forrestal S, Esposito D.

J Comp Eff Res. 2014 Nov;3(6):591-600. doi: 10.2217/cer.14.56.

PMID:
25494565
10.

Comparative effectiveness research: a progress report.

Sox HC.

Ann Intern Med. 2010 Oct 5;153(7):469-72. doi: 10.7326/0003-4819-153-7-201010050-00269. Epub 2010 Aug 2.

PMID:
20679544
11.

Comparative effectiveness research: Promising area of study for pharmacists.

Clancy CM.

J Am Pharm Assoc (2003). 2010 Mar-Apr 1;50(2):131-3. doi: 10.1331/JAPhA.2010.10501. No abstract available.

PMID:
20199952
12.

The promise and future of comparative effectiveness research.

Clancy CM.

J Nurs Care Qual. 2010 Jan-Mar;25(1):1-4. doi: 10.1097/NCQ.0b013e3181c105b7. No abstract available.

PMID:
20010250
13.

Weighing the options.

Nordenberg T.

Nature. 2010 Aug 19;466(7309):1010-1. No abstract available.

PMID:
20928944
14.

Comparative effectiveness.

Aston G.

Trustee. 2010 Jan;63(1):13-4, 19-21. No abstract available.

PMID:
20143663
15.

An evaluation of recent federal spending on comparative effectiveness research: priorities, gaps, and next steps.

Benner JS, Morrison MR, Karnes EK, Kocot SL, McClellan M.

Health Aff (Millwood). 2010 Oct;29(10):1768-76. doi: 10.1377/hlthaff.2010.0687.

PMID:
20921474
16.

Is treatment heterogeneity an Achilles' heel for comparative effectiveness research?

Alexander GC, Lambert BL.

Pharmacotherapy. 2012 Jul;32(7):583-5. doi: 10.1002/phar.1131. No abstract available.

17.

Assessing the long-term impact of public investments in comparative effectiveness research: conceptual framework and lessons learned.

Rich EC, Esposito D, Kimmey LD, Valenzano CS, Yong PL.

J Comp Eff Res. 2014 Nov;3(6):657-66. doi: 10.2217/cer.14.60.

PMID:
25494572
19.

Comparative effectiveness research (CER): a summary of AHRQ's CER on therapies for rheumatoid arthritis.

Oderda GM, Balfe LM.

J Manag Care Pharm. 2011 Nov-Dec;17(9 Suppl B):S19-24.

20.

The ARRA investment in CER: a description of the midstream evaluation and how the funds were allocated and CER priorities addressed.

Esposito D, Yong PL, Rich E, Geonnotti K, Kimmey LD.

J Comp Eff Res. 2014 Nov;3(6):581-9. doi: 10.2217/cer.14.55.

PMID:
25494564

Supplemental Content

Support Center